Durability and survival results from the phase 1b EV-103 trial provide further support for the combination of enfortumab vedotin and pembrolizumab as a promising first-line option for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.
The combination of cabozantinib and atezolizumab has antitumor activity and a manageable safety profile in men with metastatic castration-resistant prostate cancer, indicate preliminary trial data.
Results of the phase 2 ATLAS trial do not support use of the PARP inhibitor rucaparib in patients with recurrent, locally advanced, or metastatic urothelial carcinoma, the investigators have reported.
Findings from two phase 2 trials suggest that combining immune checkpoint inhibition with stereotactic body radiotherapy is feasible in patients with metastatic renal cell carcinoma.
This independent news story was supported by an educational grant from Pfizer and Merck KGaA
SEMITEP trial results reported at the 2020 Genitourinary Cancers Symposium demonstrate the feasibility of treatment de-escalation based on an interim scan in metastatic seminoma patients with good prognosis.
The adenovirus vector-based gene therapy nadofaragene firadenovec elicits durable responses in people with non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin, shows a phase 3 trial.